| abstract |
This invention relates to the use of nucleoside, nucleotide and other compounds which are inhibitors or terminators of viral RNA dependent RNA polymerases or inhibitors of exonucleases as antiviral agents. These antiviral agents can be used alone or in combination with other polymerase or exonuclease inhibitors, helicase inhibitors, HCV NS5A inhibitors, HIV integrase inhibitors and HCV NS3-4A and other protease inhibitors to treat viral infections such as SARS-CoV-2, the causative agent of the COVID-19 infection. |